Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT

David Baker, Milan Bimali, PhD, Luis Carrillo, MD, Archana Sachedina, Daisy Alapat, MD, Md shadiqul Hoque, MD, Mathew Kottarathara, MD, Richa Parikh, MD, Amani Erra, MD, Angel Mitma, MD, Pankaj Mathur, MD, Guido Tricot, MD PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Carolina D. Schinke, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-138877

Published: 2020

Journal Articles

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

Meera Mohan, MD, Samantha Kendrick, PhD, Yadav Pandey, MD, Richa Parikh, MD, Phil Farmer, Mathew Kottarathara, MD, Shadiqul Hoque, MD, Angel Mitma, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Guido Tricot, MD PhD, Maurizio Zangari, MD FACP, Frits van Rhee, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139943

Published: 2020

Journal Articles

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

Kristin Larsen, Meera Mohan, MD, Clyde Bailey, Kerri Hill, Horace Spencer, Mathew Kottarathara, MD, Richa Parikh, MD, Shadiqul Hoque, MD, Amani Erra, MD, Angel Mitma, MD, Pankaj Mathur, MD, Guido Tricot, MD PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Carolina D. Schinke, MD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-142527

Published: 2020

Journal Articles

Parathyroid Hormones (PTH) Serum Variations Are Associated with Bortezomib Response in Multiple Myeloma Patients

Maurizio Zangari, MD, Lisa Pappas, Fenghuang Zhan, MD, PhD, Naveen Sanath kumar, MD, Federica Cavallo, MD, Larry J Suva, Guido Tricot, MD, PhD, Dixie-Lee Esseltine, MD, Shmuel Yaccoby

Blood (2008) 112 (11): 2783.

https://doi.org/10.1182/blood.V112.11.2783.2783

Published: 2008

Journal Articles

Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma

Jumei Shi, MD, PhD, Susann Szmania, BS, Guido Tricot, MD, PhD, Tarun K. Garg, PhD, Priyangi A Malaviarachchi, BS, Amberly Moreno-Bost, BS, Katie Stone, BS, Fenghuang Zhan, MD, PhD, Dario Campana, MD, PhD, John Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 2758.

https://doi.org/10.1182/blood.V112.11.2758.2758

Published: 2008

Journal Articles

Metaphase Cytogenetics Adds to Gene Expression Profiling in the Identification of High Risk Multiple Myeloma.

Guido Tricot, MD, PhD, Fenghuang Zhan, MD, PhD, Bart Barlogie, MD, PhD, Yongsheng Huang, PhD, Jeffrey Sawyer, PhD, John Shaughnessy, PhD

Blood (2006) 108 (11): 114.

https://doi.org/10.1182/blood.V108.11.114.114

Published: 2006

Journal Articles

MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2.

Ronald Walker, MD, John Shaughnessy, PhD, Jeffery Haessler, MS, Joshua Epstein, DSc, Jeffery Sawyer, PhD, Elias J. Anaissie, MD, Frits Van Rhee, MD PhD, Guido Tricot, MD PhD, Maurizio Zangari, MD, Mauricio Pineda-Roman, MD, Klaus Hollmig, MD, John Crowley, MD, Bart Barlogie, MD PhD

Blood (2006) 108 (11): 3515.

https://doi.org/10.1182/blood.V108.11.3515.3515

Published: 2006

Journal Articles

Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM).

Varant Arzoumanian, MD, Bart Barlogie, MD,PhD, Mauricio Pineda-Roman, MD, Klaus Hollmig, MD, Elias Anaissie, MD, Maurizio Zangari, MD, Somashekar Krishna, MD, Eilas Kiwan, MD, Guido Tricot, MD,PhD, Abid Mohiuddin, MD, Frits van Rhee, MD,PhD

Blood (2006) 108 (11): 3561.

https://doi.org/10.1182/blood.V108.11.3561.3561

Published: 2006

Journal Articles

DNA Repair Genes Are Upregulated in Multiple Myeloma (MM) Patients Relapsing after Tandem Transplantation.

Guido Tricot, MD, PhD, Fenghuang Zhan, MD, PhD, Yongsheng Huang, PhD, Bart Barlogie, MD, PhD, John Shaughnessy, PhD

Blood (2006) 108 (11): 3392.

https://doi.org/10.1182/blood.V108.11.3392.3392

Published: 2006

Journal Articles

Retrospective Analysis of Fractionated High-Dose Melphalan (F-MEL) and Bortezomib-Thalidomide-Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple Myeloma (AR-MM).

Mauricio Pineda-Roman, MD, Michelle H. Fox, MD, Klaus A. Hollmig, MD, Elias J. Anaissie, MD, Frits van Rhee, MD,PhD, Guido Tricot, MD,PhD, Maurizio Zangari, MD, Abid Mohiuddin, MD, Bart Barlogie, MD,PhD

Blood (2006) 108 (11): 3102.

https://doi.org/10.1182/blood.V108.11.3102.3102

Published: 2006

Journal Articles

Bortezomib Down-Regulates HLA Class I and Enhances Natural Killer Cell Mediated Lysis of Myeloma.

Jumei Shi, MD, PhD, Tarun K. Garg, PhD, Rachel E. Kellum, BS, Susann M. Szmania, BS, Bart Barlogie, MD, PhD, Guido Tricot, MD, PhD, Frits van Rhee, MD, PhD

Blood (2006) 108 (11): 3498.

https://doi.org/10.1182/blood.V108.11.3498.3498

Published: 2006

Journal Articles

Lack of Predictive Value of KIR-HLA Genotypes for Autologous Transplant Outcome for Multiple Myeloma.

Katharine C. Hsu, MD, PhD, Guido Tricot, MD PhD, Jeff Haessler, PhD, Clara Pinto-Agnello, MS, Frits van Rhee, MD PhD, Michelle Fox, MD, Bo Dupont, MD DSc

Blood (2006) 108 (11): 3078.

https://doi.org/10.1182/blood.V108.11.3078.3078

Published: 2006

Journal Articles

CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.

Susann Szmania, BS, Balaji Balasa, PhD, Priyangi Malaviarachchi, BS, Fenguhuang Zhan, MD,PhD, Yongsheng Huang, MS, Aparna Draksharapu, MD, Vladimir Vexler, PhD, John Shaughnessy, Jr., PhD, Bart Barlogie, MD,PhD, Guido Tricot, MD,PhD, Daniel Afar, PhD, van Rhee Frits, MD,PhD

Blood (2006) 108 (11): 660.

https://doi.org/10.1182/blood.V108.11.660.660

Published: 2006

Journal Articles

Mobilization of Stem Cells with DT-PACE Plus Pegfilgrastim vs. DT-PACE Plus Filgrastim in Previously Treated MM Patients.

Guido Tricot, MD, PhD, Maureen Reiner, MS, Michael Burns, BS, Maurizio Zangari, MD, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD, Michele Cottler-Fox, MD

Blood (2005) 106 (11): 1972.

https://doi.org/10.1182/blood.V106.11.1972.1972

Published: 2005

Journal Articles

Variables Predicting for Poor Mobilization of Peripheral Blood Stem Cells (PBSC) in Newly Diagnosed Myeloma Patients, Treated on TT-2 Protocol.

Frederica Cavallo, MD, Vanessa Bolejak, MPH, Michele Cottler-Fox, MD, Antje Hoering, PhD, Frits van Rhee, MD, PhD, Maurizio Zangari, MD, Guido Tricot, MD, PhD

Blood (2005) 106 (11): 1981.

https://doi.org/10.1182/blood.V106.11.1981.1981

Published: 2005

Journal Articles

Vaccination with MAGE-3 Protein Can Induce a Potent Immune Response in a Healthy Donor Which Can Be Adoptively Transferred Via Stem Cell Transplant (Tx) to a Multiple Myeloma (MM) Patient.

Sacha Gnjatic, PhD, Susann Szmania, BS, Amberly Moreno, BS, M. Cottler-Fox, MD, John Shaughnessy, MD, Bart Barlogie, MD, PhD, Lloyd Old, PhD, Guido Tricot, MD, PhD, Frits van Rhee, MD, PhD

Blood (2005) 106 (11): 2197.

https://doi.org/10.1182/blood.V106.11.2197.2197

Published: 2005

Journal Articles

Stimulation with K562 Cells Transfected with 4-1BBL and IL-15 Expands and Activates Natural Killer (NK) Cells with Specific Cytotoxicity for Multiple Myeloma (MM).

Jumei Shi, MD, PhD, Guido Tricot, MD, PhD, Susann Szmania, BS, Cristyn Camet, BS, Nancy Rosen, BS, Michele Cottler-Fox, MD, Bart Barlogie, MD, PhD, Dario Campana, MD, PhD, Frits van Rhee, MD, PhD

Blood (2005) 106 (11): 3392.

https://doi.org/10.1182/blood.V106.11.3392.3392

Published: 2005

Journal Articles

Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma.

Ronald Walker, MD, Erik Rasmussen, MS, Federica Cavallo, MD, Laurie Jones-Jackson, MD, Elias Anaissie, MD, Terri Alpe, BS, Joshua Epstein, DSc, Frits Van Rhee, MD, PhD, Maurizio Zangari, MD, Guido Tricot, MD, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD

Blood (2005) 106 (11): 3493.

https://doi.org/10.1182/blood.V106.11.3493.3493

Published: 2005

Journal Articles

Melphalan 200mg/m 2 (MEL 200) and MEL 140/DT-PACE Are Equally Effective in Multiple Myeloma (MM), While the Latter Is Less Toxic.

Guido Tricot, MD, PhD, Maureen Reiner, MS, Maurizio Zangari, MD, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD

Blood (2005) 106 (11): 839.

https://doi.org/10.1182/blood.V106.11.839.839

Published: 2005

Journal Articles

The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does.

Guido Tricot, MD, PhD, Maureen Reiner, MS, Maurizio Zangari, MD, Frits van Rhee, MD, PhD, Elias Anaissie, MD, Teresa Milner, BS, Bart Barlogie, MD, PhD

Blood (2005) 106 (11): 1157.

https://doi.org/10.1182/blood.V106.11.1157.1157

Published: 2005

NARROW

Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

Parathyroid Hormones (PTH) Serum Variations Are Associated with Bortezomib Response in Multiple Myeloma Patients

Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma

Metaphase Cytogenetics Adds to Gene Expression Profiling in the Identification of High Risk Multiple Myeloma.

MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2.

Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM).

DNA Repair Genes Are Upregulated in Multiple Myeloma (MM) Patients Relapsing after Tandem Transplantation.

Retrospective Analysis of Fractionated High-Dose Melphalan (F-MEL) and Bortezomib-Thalidomide-Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple Myeloma (AR-MM).

Bortezomib Down-Regulates HLA Class I and Enhances Natural Killer Cell Mediated Lysis of Myeloma.

Lack of Predictive Value of KIR-HLA Genotypes for Autologous Transplant Outcome for Multiple Myeloma.

CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.

Mobilization of Stem Cells with DT-PACE Plus Pegfilgrastim vs. DT-PACE Plus Filgrastim in Previously Treated MM Patients.

Variables Predicting for Poor Mobilization of Peripheral Blood Stem Cells (PBSC) in Newly Diagnosed Myeloma Patients, Treated on TT-2 Protocol.

Vaccination with MAGE-3 Protein Can Induce a Potent Immune Response in a Healthy Donor Which Can Be Adoptively Transferred Via Stem Cell Transplant (Tx) to a Multiple Myeloma (MM) Patient.

Stimulation with K562 Cells Transfected with 4-1BBL and IL-15 Expands and Activates Natural Killer (NK) Cells with Specific Cytotoxicity for Multiple Myeloma (MM).

Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma.

Melphalan 200mg/m 2 (MEL 200) and MEL 140/DT-PACE Are Equally Effective in Multiple Myeloma (MM), While the Latter Is Less Toxic.

The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only